RxDoctor Payments Data

Brittney Knight

Family · Terre Haute, INNPI 1699554360

Payments from drug & device makers

$2,206in general payments, 2019–2025

Across 77 payments — averaging $28.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$390
  • Harmony Biosciences LLC$332
  • Boehringer Ingelheim$278
  • GSK$204
  • Takeda Pharmaceuticals U.S.A., Inc.$189
  • AstraZeneca$180
  • plus $633 from 13 others

What the payments were for

  • Food & beverage$1,99690%
  • Education$21010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,206 in reported general payments places this provider in the 80th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$43,090
Medicare patients
220
Services billed
835

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VoqueznaVonoprazan Fumarate14$13,975
Azelastine Hcl72$1,755
Fluticasone Propionate95$1,157
Omeprazole82$904
Ofloxacin25$612
Fluocinolone Acetonide Oil15$588
Clotrimazole18$538
Mupirocin64$452
Albuterol Sulfate HfaAlbuterol Sulfate13$357
Pantoprazole Sodium43$313
Doxycycline Monohydrate17$309
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav22$273
Montelukast Sodium11$139
Gentamicin Sulfate13$125
Methylprednisolone12$73

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Phathom Pharmaceuticals, Inc.Voquezna$390$13,97514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,392 family providers in Indiana.

Other family in Terre Haute

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →